Psychoactive drug prescription and urine colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae

References

• Spellberg B, Blaser M, Guidos RJ, et al.; Infectious Diseases Society of America (IDSA). Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(Suppl 5):S397–S428. doi:10.1093/cid/cir153.21474585
   PubMed Web of Science ®Google Scholar
• Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–166. doi:10.1016/S1473-3099(08)70041-018291338
   PubMed Web of Science ®Google Scholar
• Paterson DL. Collateral damage from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):SS341–SS345. doi:10.1086/382690
   Web of Science ®Google Scholar
• Surveillance of antimicrobial resistance in Europe 2017 European Centre for Disease Prevention and Control; 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2017. Accessed June 17, 2019.
   Google Scholar
• Haber N, Paute J, Gouot A, et al. [Incidence and clinical characteristics of symptomatic urinary infections in a geriatric hospital]. Med Mal Infect. 2007;37(10):664–672.17337143
   PubMed Web of Science ®Google Scholar
• Jørgensen SB, Søraas A, Sundsfjord A, Liestøl K, Leegaard TM, Jenum PA. Fecal carriage of extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae after urinary tract infection - A three year prospective cohort study. PLoS One. 2017;12(3):e0173510. doi:10.1371/journal.pone.017351028267783
   PubMed Web of Science ®Google Scholar
• Ruppé E, Lixandru B, Cojocaru R, et al. Relative fecal abundance of extended-spectrum-β-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women. Antimicrob Agents Chemother. 2013;57(9):4512–4517. doi:10.1128/AAC.00238-1323836184
   PubMed Web of Science ®Google Scholar
• Flokas ME, Alevizakos M, Shehadeh F, Andreatos N, Mylonakis E. Extended-spectrum β-lactamase-producing Enterobacteriaceae colonisation in long-term care facilities: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;50(5):649–656. doi:10.1016/j.ijantimicag.2017.08.00328782707
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-β-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55(7):3485–3490. doi:10.1128/AAC.01370-1021537020
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51(6):1987–1994. doi:10.1128/AAC.01509-0617387156
   PubMed Web of Science ®Google Scholar
• Babu R, Kumar A, Karim S, et al. Faecal carriage rate of extended-spectrum β-lactamase-producing Enterobacteriaceae in hospitalised patients and healthy asymptomatic individuals coming for health check-up. J Glob Antimicrob Resist. 2016;6:150–153. doi:10.1016/j.jgar.2016.05.00727530858
   PubMed Web of Science ®Google Scholar
• Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013;56(5):641–648. doi:10.1093/cid/cis94223150211
   PubMed Web of Science ®Google Scholar
• van Schaik W. The human gut resistome. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140087. doi:10.1098/rstb.2014.023025918444
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, López-Cerero L, Navarro MD, Díaz de Alba P, Pascual A. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother. 2008;62(5):1142–1149. doi:10.1093/jac/dkn29318641033
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Schwaber MJ, Navon-Venezia S, et al. Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis. 2006;42(7):925–934. doi:10.1086/50093616511754
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Bonner A, Berwick DM. Reducing excessive use of antipsychotic agents in nursing homes. Jama. 2017;318(2):118–119. doi:10.1001/jama.2017.703228617907
   PubMed Web of Science ®Google Scholar
• Cederlund H, Mårdh PA. Antibacterial activities of non-antibiotic drugs. J Antimicrob Chemother. 1993;32(3):355–365. doi:10.1093/jac/32.3.3558262858
   PubMed Web of Science ®Google Scholar
• Kristiansen JE. The antimicrobial activity of non-antibiotics. Report from a congress on the antimicrobial effect of drugs other than antibiotics on bacteria, viruses, protozoa, and other organisms. APMIS Suppl. 1992;30:7‑14.
   Google Scholar
• Muñoz-Bellido JL, Muñoz-Criado S, García-Rodríguez JA. In-vitro activity of psychiatric drugs against Corynebacterium urealyticum (Corynebacterium group D2). J Antimicrob Chemother. 1996;37(5):1005–1009.8737151
   PubMed Web of Science ®Google Scholar
• Bahr SM, Tyler BC, Wooldridge N, et al. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015;5:e652. doi:10.1038/tp.2015.13526440540
   PubMed Web of Science ®Google Scholar
• Chapelet G, Corvec S, Montassier E, et al. Rapid detection of amoxicillin-susceptible Escherichia coli in fresh uncultured urine: a new tool to limit the use of broad-spectrum empirical therapy of community-acquired pyelonephritis. Int J Antimicrob Agents. 2016;47(6):486–489. doi:10.1016/j.ijantimicag.2016.04.01227211827
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints for bacteria; 2015 Available from: http://www.eucast.org/clinical_breakpoints/.  Accessed June 17, 2019.
   Google Scholar
• Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(Suppl 2):S82–S89. doi:10.1086/49940616355321
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Rodríguez-Baño J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49(5):682–690. doi:10.1086/64794219622043
   PubMed Web of Science ®Google Scholar
• Sharma S, Singh A. Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications. Expert Opin Investig Drugs. 2011;20(12):1665–1676. doi:10.1517/13543784.2011.628657
   PubMed Web of Science ®Google Scholar
• Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–748. doi:10.1136/gutjnl-2015-31037626657899
   PubMed Web of Science ®Google Scholar
• Rogers MA, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 2016;22(2):178.e1–178.e9. doi:10.1016/j.cmi.2015.10.003
   PubMed Web of Science ®Google Scholar
• Morgan AP, Crowley JJ, Nonneman RJ, et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS One. 2014;9(12):e115225. doi:10.1371/journal.pone.011522525506936
   PubMed Web of Science ®Google Scholar
• Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262–266. doi:10.1038/nature1576626633628
   PubMed Web of Science ®Google Scholar
• Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623–628. doi:10.1038/nature2597929555994
   PubMed Web of Science ®Google Scholar